Navigation Links
AEterna Zentaris Announces Completion of Phase 1 Study with Oral AEZS-112 in Cancer
Date:9/21/2009

cokinetic study on weekly oral AEZS-112, a small molecule anti-cancer agent in patients with advanced cancer and lymphoma", was presented by D. W. Northfelt, M.D.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are required by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
2. AEterna Zentaris to Present at Upcoming Rodman Renshaw Annual Global Investment Conference
3. AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Reports Second Quarter 2009 Financial and Operating Results
5. AEterna Zentaris to Present at Upcoming Canaccord Adams 29th Annual Global Growth Conference
6. AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
7. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction
9. AEterna Zentaris Receives US$10 Million from Institutional Investors
10. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
11. AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Worms, Germany (PRWEB) May 21, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACT™, an independent subsidiary of the International Pharmaceutical ... three Grace facilities that produce its SYLOID® FP ... now received GMP certification, following the Curtis Bay, ...
(Date:5/21/2015)... May 21, 2015 As part of ... Center (BDWMC), Sun Health Foundation funded a $3.25 million ... inpatient pharmacy with the most up-to-date features and technology. ... 2. The pharmacy's 45 staff members will begin moving ... space in the coming days. , The current ...
(Date:5/21/2015)... 21, 2015 Veolia’s environmental monitoring ... North American distribution agreement with VWR to distribute ... With more than 160 years of experience, VWR, ... for laboratory and production facilities, has cultivated a ... differentiated services to enable science. Endetec’s TECTA™ ...
(Date:5/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has ... HW_Technical Insights" report to their offering. ... in the Health and Wellness sector and has identified ... impact in the year 2015. The research service provides ... and wellness technologies that are anticipated to have the ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Top Technologies in the Health and Wellness Industry 2015 2
... April 22 BioMed Realty Trust, Inc. (NYSE: ... Realty, L.P., priced a private placement of $250 million aggregate ... of face value.  The Notes will be senior unsecured obligations of the ... Trust, Inc. , , , ...
... InterMune, Inc. (Nasdaq: ITMN ) announced today that it will ... at 4:00 p.m. Eastern time .  A live conference call ... time that same day. , ... To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), ...
... ... food production. Technologies that grow more from less improve eco-efficiency., , ... (PRWEB) April 22, 2010 -- On ... of the Sustainability Consortium , an independent group of diverse stakeholders working to ...
Cached Biology Technology:BioMed Realty, L.P. Prices Private Offering of $250 Million of 6.125% Senior Unsecured Notes Due 2020 2BioMed Realty, L.P. Prices Private Offering of $250 Million of 6.125% Senior Unsecured Notes Due 2020 3InterMune to Release First Quarter Financial Results on April 29 2Syngenta joins Sustainability Consortium as Founding Member 2Syngenta joins Sustainability Consortium as Founding Member 3
(Date:4/27/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... the first week of May, 2015 and will be ... Gino Pereira , Chief Executive ... company as Wocket® enters the consumer market. We would ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
(Date:4/20/2015)... April 20, 2015 The announcement ... Glenbeigh Records Management (GRM), Ireland,s ... Islamic Bank. Having built up an impressive track record of ... leading player within the records management sector in ... double is GCC staffbase and employ a further eight staff ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... one scratchy tune learned in its youth, which it ... occasionally, the finch might improvise, experimenting with a slower, ... studying the finch now say the improvisation arises from ... section of the forebrain that seems to generate the ...
... in St. Louis have discovered an entirely new cellular ... plant flowering and DNA methylation, a key chemical process ... by Craig Pikaard, Ph, D., Washington University professor of ... kind of RNA polymerase found only in plants and ...
... (CLL) is an incurable disease in which cells in the ... become abnormal and malignant (leukemic). The progression of the disease ... regarding the rate of production of CLL cells, and the ... believed that CLL was a static disease of long-lived lymphocytes ...
Cached Biology News:Bird Brains Show How Trial and Error May Contribute to Learning 2Bird Brains Show How Trial and Error May Contribute to Learning 3New RNA polymerase discovered in plants 2New RNA polymerase discovered in plants 3The very unexpected life and death of a leukemic cell 2
Request Info...
Chemically Defined Lipid Concentrate...
Goat polyclonal to PINX1 ( Abpromise for all tested applications). entrezGeneID: 54984 SwissProtID: Q548A5...
... membrane-filtered isotonic and enzyme-free aqueous formulations ... agents in either Ca2+- and Mg2+-free ... Ca2+- and Mg2+-free phosphate-buffered saline for ... support substrates and each other for ...
Biology Products: